Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MLF1 CRISPR/Cas9 KO Plasmid (h): sc-417753
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MLF1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MLF1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MLF1 Antibody (D-1): sc-514294
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MLF1 CRISPR/Cas9 KO Plasmid (h) | sc-417753 | 20 µg | $397.00 |
Overview
Myeloid leukemia factor 1 (MLF1) is a conserved regulator of hematopoietic cell fate that localizes to both cytoplasm and nucleus and participates in protein–protein interactions influencing transcriptional programs and cell-cycle control. It has been linked to myeloid differentiation and stress-responsive signaling, with reported roles in modulating apoptotic susceptibility and proliferative capacity in lineage-committed cells. Altered MLF1 expression or mislocalization has been associated with hematologic malignancy biology, including leukemic transformation contexts where differentiation and growth checkpoints are disrupted. As a result, MLF1 serves as a useful node for studying pathways that couple transcriptional regulation to proliferation and differentiation in human cells.
MLF1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MLF1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MLF1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MLF1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MLF1 protein expression.
This CRISPR knockout system enables efficient generation of MLF1-deficient cell models for investigation of MLF1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MLF1 exon(s) critical for MLF1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MLF1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MLF1 CRISPR/Cas9 KO Plasmid (h) and MLF1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MLF1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MLF1 HDR Plasmid (h) and MLF1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MLF1 homology arms to support homology-directed repair at defined MLF1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.